Top 50 Medical VC Funds & Investors in China (September 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
56 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.4M–$120M |
|
BioVenture
VC Fund
|
40 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $4.4M–$73M |
|
HSG
VC Fund
|
38 | China, United States, Australia | Series B, Series A, Seed | Artificial Intelligence, Biotechnology, Software | $2M–$226M |
|
Med-Fine Capital
VC Fund
|
29 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $3M–$60M |
|
Legend Capital
VC Fund
|
29 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $1.6M–$200M |
|
Frees Fund
VC Fund
|
26 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $447k–$35M |
|
Matrix Partners China
VC Fund
|
25 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Biotechnology | $1.6M–$137M |
|
Shenzhen Capital Group
VC Fund
|
23 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.5M–$156M |
|
Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
|
23 | China, United States, Hong Kong | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $8M–$159M |
|
IDG Capital
VC Fund
|
22 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $2.9M–$354M |
|
Lilly Asia Ventures
VC Fund
|
22 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
Taiyu Investment
VC Fund
|
22 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $434k–$100M |
|
Cowin Venture
VC Fund
|
21 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Medical, Biotechnology | $425k–$257M |
|
Prox Ventures
VC Fund
|
21 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$28M |
|
Northern Light Venture Capital
VC Fund
|
21 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.3M–$60M |
|
Puhua Capital
VC Fund
|
21 | China, United Kingdom, United States | Series A, Series B, Seed | Health Care, Medical, Manufacturing | $1.5M–$103M |
|
Longpan Investment
VC Fund
|
20 | China, United States, Cayman Islands | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $14M–$60M |
|
Marathon Venture Partners
VC Fund
|
20 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.4M–$142M |
|
Lenovo Capital and Incubator Group (LCIG)
VC Fund
|
19 | China, Hong Kong, United States | Series A, Seed, Series B | Manufacturing, Artificial Intelligence, Software | $1.4M–$150M |
|
Legend Star
VC Fund
|
18 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Biotechnology | $425k–$52M |
|
Cowin Capital
VC Fund
|
17 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$51M |
|
Highlight Capital
VC Fund
|
17 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3M–$84M |
|
Dalton Venture
VC Fund
|
16 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $512k–$50M |
|
Huagai Capital
VC Fund
|
15 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $425k–$90M |
|
ZSVC
VC Fund
|
15 | China, United States, India | Series A, Seed, Series B | Manufacturing, Medical, Health Care | $1.4M–$84M |
|
Share Capital
VC Fund
|
15 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $142k–$93M |
|
BioTrack Capital
VC Fund
|
15 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
CDH Investments
VC Fund
|
15 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Biotechnology, Health Care | $7.3M–$220M |
|
Haiyuan Capital
VC Fund
|
14 | China | Series A, Seed, Angel | Manufacturing, Medical, Semiconductor | $432k–$15M |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
14 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Medical | $223k–$60M |
|
Cenova
VC Fund
|
13 | China, United States, Hong Kong | Series B, Series A, Series C | Medical, Health Care, Biotechnology | $2.8M–$100M |
|
Sherpa Healthcare Partners
VC Fund
|
13 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7.2M–$128M |
|
Hillhouse Investment
VC Fund
|
13 | China, United States, Singapore | Series A, Series B, Series C | Manufacturing, Software, Biotechnology | $2.9M–$300M |
|
EFung Capital
VC Fund
|
13 | China, United States, India | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $1.4M–$100M |
|
Kaitai Capital
VC Fund
|
12 | China, United States, Singapore | Series A, Seed, Series B | Biotechnology, Health Care, Pharmaceutical | $1.4M–$57M |
|
Pan-Lin Capital
VC Fund
|
12 | China, United States, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $1.4k–$58M |
|
Shunwei Capital
VC Fund
|
12 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.5M–$105M |
|
Oriental Fortune Capital
VC Fund
|
12 | China, United States | Series A, Series B, Seed | Software, Manufacturing, Information Technology | $1.4M–$100M |
|
Addor Capital
VC Fund
|
12 | China, Hong Kong, Singapore | Series A, Series B, Seed | Manufacturing, Semiconductor, Electronics | $1.4k–$47M |
|
ZhenFund
VC Fund
|
12 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Software, E-Commerce | $425k–$30M |
|
Sunland Fund
VC Fund
|
11 | China | Series A, Series B, Seed | Health Care, Medical, Medical Device | $1.4M–$28M |
|
Long Hill Capital
VC Fund
|
11 | China, United States | Series A, Series B, Series C | Medical, Health Care, Training | $1.9M–$60M |
|
Fortune Venture Capital
VC Fund
|
11 | China, Japan, United States | Series A, Series B, Seed | Manufacturing, Software, Information Technology | $462k–$73M |
|
Sinovation Ventures
VC Fund
|
10 | China, United States, Hong Kong | Series A, Seed, Series B | Artificial Intelligence, Software, Health Care | $1.3M–$74M |
|
Oriza Holdings
VC Fund
|
10 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $1.5M–$200M |
|
Green Pine Capital Partners
VC Fund
|
10 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Biotechnology, Software | $425k–$150M |
|
K2VC
VC Fund
|
10 | China, United States, Hong Kong | Series A, Angel, Seed | E-Commerce, Manufacturing, Software | $425k–$38M |
|
Lotus Lake Ventures
VC Fund
|
10 | China, India | Series A, Series B, Seed | Medical, Health Care, Biotechnology | $42k–$97M |
|
Tiantu Capital
VC Fund
|
10 | China, United States, Japan | Series A, Series B, Seed | Food and Beverage, E-Commerce, Health Care | $1.5M–$146M |
|
Beijing Huafang Investment
VC Fund
|
10 | China | Series A, Seed, Angel | Biotechnology, Medical, Biopharma | $13M–$30M |
| Access all 3480 VC funds in China Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 1112
- Round size: Series A $4.4M–$50M; Series B $8.5M–$88M; Series C $12M–$120M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Guangjing Energy — Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 189
- Round size: Seed $7.9M–$41M; Series A $4.4M–$47M; Series B $7.1M–$73M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $204M in 2016
Portfolio highlights
- SiranBio — SiranBio is a biotechnology that develops innovative siRNA drugs.
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Software
- Stage:Series B, Series A, Seed
- Geography: China, United States, Australia
Investor stats
- Total investments: 970
- Round size: Seed $2M–$50M; Series A $4.4M–$100M; Series B $12M–$226M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $2.5B in 2024
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $3M–$40M; Series B $12M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $73M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 481
- Round size: Series A $1.6M–$93M; Series B $11M–$107M; Series C $15M–$200M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
- Shunyuan Technology — Shunyuan Technology is a high-tech enterprise specializing in the development of fusion simulators and advanced route design solutions, providing innovative technologies and intelligent systems for complex engineering, transportation, and industrial applications.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 229
- Round size: Seed $1.4M–$14M; Angel $447k–$14M; Series A $1.4M–$35M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $144M in 2015
Portfolio highlights
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
- Flysound — Flysound is a hearing technology company focused on making advanced AI-powered hearing aids affordable and accessible. Its products combine AI sound processing, Bluetooth connectivity, app-based personalization, and rechargeable convenience. With a focus on innovation, quality, and user-friendly design, Flysound aims to help people hear moreclearly and stay connected to everyday life.
- Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 622
- Round size: Seed $1.6M–$74M; Series A $2.9M–$61M; Series B $10M–$137M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $92M in 2023
Portfolio highlights
- Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
- Camera360 — Camera360 is a professional but easy-to use App for photo editing and selfie retouching. Tag #camera360
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 601
- Round size: Series A $1.5M–$128M; Series B $13M–$141M; Series C $4.4M–$156M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 68
- Round size: Seed $8M–$50M; Series A $14M–$43M; Series B $10M–$159M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- BioGeometry — Reshaping the world, one protein at a time
- Surgerii Technology — Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.
- Beyond Therapeutics — Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 1057
- Round size: Series A $2.9M–$100M; Series B $7.1M–$115M; Series C $15M–$354M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- AIxCrypto — Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of its flagship FastPack® diagnostic platform.
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Chengjia Apartment — Chengjia Apartment is a rental start-up that provides different product choices for apartments, hotels, and homestays. Chengjia Apartment extends the business scope to weekly rent, monthly rent, and long-term rent. The company creates a high-quality living environment with ingenuity, take care of every guest with hotel-style service, and creates awarm, comfortable, and temperature-friendly home.Chengjia Apartment is jointly established by China Living Hotel Group and IDG Capital. It has laid out nearly 100 properties in first-tier cities nationwide, with more than 10,000 houses and services.It was founded on 2015 and is headquartered in Shanghai, China.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 244
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Abogen Biosciences — Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 49
- Round size: Seed $2.8M–$20M; Angel $434k–$100M; Series A $13M–$29M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 104
- Round size: Angel $425k–$1.4M; Series A $1.5M–$25M; Series B $2.8M–$257M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
- Diling Technology — Diling Technology is a comprehensive, one-stop content security solution provider, specializing in the identification and management of content-related security risks.
- StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 82
- Round size: Seed $2.5M–$14M; Series A $3M–$28M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 360
- Round size: Seed $1.3M–$60M; Series A $2.9M–$40M; Series B $10M–$58M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Health Care, Medical, Manufacturing
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 272
- Round size: Seed $2.3M–$29M; Series A $1.5M–$42M; Series B $3M–$103M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Nuoyun Drive —
- Ganzhicao Technology — Gancao Doctor is an internet-based Traditional Chinese Medicine (TCM) company that helps clinics modernize their digital management and optimize operations. By using AI-assisted features, it enhances doctors' diagnostic and treatment abilities, delivering valuable benefits to doctors, patients, and clinics.
- Interstellar Lightyear — Interstellar Lightyear Technology is a developer specializing in dexterous robotic hands, focusing on creating intelligent dexterous hands with advanced capabilities for precise manipulation.
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 44
- Round size: Seed $14M–$60M; Series A $14M–$32M; Series B $14M–$37M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
- Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.4M–$29M; Series B $14M–$142M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Lenovo Capital and Incubator Group is an accelerator and venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Software
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 342
- Round size: Seed $1.4M–$42M; Series A $1.5M–$74M; Series B $8M–$150M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $500M in 2016
Portfolio highlights
- Violoop — Violoop is a Chinese AI hardware startup Specializes in AI-PC automation hardware as a "physical-level AI Operator", bridging legacy software and AI agents for 24/7 workflows without APIs.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 161
- Round size: Seed $1.5M–$19M; Angel $425k–$49M; Series A $1.5M–$52M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — raised $127M in 2018
Portfolio highlights
- CellWall — Cellwall is a desktop robot developer focused on the research, development, upgrade, and marketing of its initial product, CyboPal ONE.
- Yuanhao Power — The primary focus of Yuanhao Power, an AI native technology developer, is the creation of fifth-generation multimodal 4D world model base models. It creates a cohesive model system that encompasses dynamic environment reconstruction, generation, simulation, and intelligent agent training, and it encourages its use in applications like autonomousdriving, medical procedures, games and movies, and embodied intelligence. For the era of physical AI, it is dedicated to developing a universal world model base.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 345
- Round size: Seed $1.4M–$20M; Series A $4.3M–$51M; Series B $2.8M–$50M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Sunrise — Sunrise is a high-performance GPU developer specializing in GPU research and development.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 177
- Round size: Seed $10M–$84M; Series A $3M–$73M; Series B $7.6M–$70M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Genuine Rhythm — Genuine Rhythm is an innovative AI Agent technology developer specializing in bespoke agent creation, advanced algorithm R&D, and rigorous security compliance solutions tailored to diverse enterprise needs.
- PoShell Robotics — PoShell Robotics is a general-purpose home robot, aiming to create a home-friendly and structurally stable robot.
- Xunlu Innovation — Xunlu Innovation is a cutting-edge bicycle manufacturer based in Shenzhen, China, specializing in intelligent electric cargo bikes designed to meet modern urban mobility needs.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 142
- Round size: Seed $512k–$5M; Series A $2.9M–$17M; Series B $2.8M–$50M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 150
- Round size: Angel $425k–$15M; Series A $1.4M–$73M; Series B $3.5M–$90M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
- Falcon Technology — Falcon Technology focuses on DSA processor design innovation, developing a dedicated computing technology ecosystem based on the RISC-V architecture to deliver high-performance, energy-efficient processing solutions for next-generation intelligent computing applications.
ZSVC is a Chinese venture capital firm specialized in seed and early stage investments.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, India
Investor stats
- Total investments: 144
- Round size: Seed $1.4M–$4M; Series A $1.5M–$21M; Series B $2.8M–$84M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Tpson — Tpson is a Smart Hardware company.
- Ounuo Semiconductor — Ounuo Semiconductor is a manufacturing company that provides research and development of semiconductor equipment.
- HUAXI Technology — HUAXI Technology is a global leader specializing in the development and delivery of comprehensive, high-end smart elderly care solutions. By integrating advanced technologies such as the Internet of Things (IoT), artificial intelligence (AI), and big data analytics, the company is dedicated to enhancing the quality of life for seniors worldwide.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 94
- Round size: Seed $15M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Taiyi Quantum — Taiyi Quantum is dedicated to encouraging innovation in the distribution and implementation of quantum computing technology, as well as developing sophisticated quantum algorithms and delivering tailored computing solutions for businesses and research institutes.
- Convergen — Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 316
- Round size: Series A $7.3M–$100M; Series B $14M–$141M; Series C $30M–$220M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- kokoni — kokoni is an innovative, user-friendly 3D printer brand owned by Moxin (Huzhou) Technology Co., LTD
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- Weiling Medical — Wiling Medical offers extensive knowledge of the principles and clinical uses of implantable brain-computer interfaces as well as extensive experience in basic research engineering practise, and clinical care.
Goldport Capital is a Shenzhen-based asset management company.
Show more...Investment focus
- Industry: Manufacturing, Medical, Semiconductor
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 74
- Round size: Seed $1.4M–$15M; Angel $432k–$14M; Series A $1.4M–$15M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Anxin Medical — Anxin Medical is a company dedicated to the research, development, production, and sales of innovative medical devices. The company focuses on advancing healthcare technology through continuous innovation, integrating cutting-edge science and engineering to create high-quality, reliable, and efficient medical products.
- Hongxin Biology — Hongxin Bio is an mRNA drug developer, focusing on nucleic acid drug delivery and RNA drug development.
- Huaiye Information — Huaiye Information is a high-tech enterprise specializing in audio and video streaming technologies.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 151
- Round size: Seed $223k–$25M; Angel $425k–$15M; Series A $1.4M–$60M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Youshu Quantum — Youshu Quantum is a deep-tech startup specializing in quantum computing software, middleware, and proprietary algorithms.
- Jitian Xingzhou — Jitian Xingzhou is a commercial aerospace company that provides optical main payloads in batches as one of its primary operations.
- Thortime Technology — Thortime Technology is a hard-tech company specializing in the full-stack development, manufacturing, and delivery of Neutral Beam Injection systems for controllable nuclear fusion devices.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Cenova Capital is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU and is one of the earliest investors in private healthcare services and digital health, with helps to facilitate the transformation of healthcare in China from an exclusively state-owned system to a more efficient, market-oriented system. CenovaCapital is healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sector in China. Since inception in 2010, Cenova now has five funds under management with investments in over 50 companies in healthcare services, pharmaceuticals, medical devices and digital heath. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 60
- Round size: Series A $2.8M–$45M; Series B $13M–$61M; Series C $15M–$100M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Simnova — Simnova Biotherapeutics is a biopharmaceutical company that focuses on the research and development of cell therapies for cancer treatment. The company's primary therapeutic focus is CAR-based cell therapy for patients with either hematologic malignancies or solid tumors. Simnova Biotherapeutics is known for its innovative approach todeveloping patient-centered therapeutics using current science and technology. The company's lead product is SNC102, a cell therapy product that has been approved for clinical trials. Simnova Biotherapeutics is committed to creating a healthy, inclusive, and harmonious working environment.
- Deep Cell — Deep Cell is a Chinese AI driven drug discovery and virtual cell modeling startup. The company integrates artificial intelligence with multi scale molecular physics to construct explainable virtual cell world models, aiming to revolutionize paradigm shifting drug designs and simulate cellular responses to complex diseases.
- Accro Bioscience — Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis.
Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 103
- Round size: Series A $7.2M–$50M; Series B $15M–$100M; Series C $21M–$128M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- Shenfu Jianxing — Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Manufacturing, Software, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 430
- Round size: Series A $2.9M–$153M; Series B $14M–$230M; Series C $15M–$300M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $1.4B in 2023
Portfolio highlights
- Qianjue Robot — Qianjue Robot researches and develops multimodal tactile perception and intelligence technologies for precision robot operations.
- The Snow League — The Future of Winter Sports Competition | Founded by @ShaunWhite
- DayOne — GDS International portfolio currently comprises approximately 480 MW of data center capacity in service and under construction and an additional 590 MW held for future development across strategic locations in Hong Kong, Singapore, Malaysia (Johor), Indonesia (Batam), and Japan (Tokyo).
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 84
- Round size: Series A $1.4M–$36M; Series B $14M–$100M; Series C $14M–$74M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Xinyun Life — Xinyun Life Sciences is a high tech medical enterprise focusing on the R&D and industrialization of artificial intelligence vascular intervention devices. The company integrates AI deeply into its hardware development using a unique dual closed- oop system.
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
- Heluo New Image — Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development.
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 159
- Round size: Seed $1.4M–$20M; Series A $1.5M–$35M; Series B $10M–$57M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- Deep Intelligent Pharma — Deep Intelligent Pharma (DIP) is a Singapore-based AI company that helps pharmaceutical and biotech companies run clinical trials faster, cheaper, and with fewer mistakes. Its AI platform automates many slow and manual tasks, such as writing trial documents, designing studies, analyzing data, translating medical content for global regulators, andpreparing regulatory submissions. By using thousands of small AI agents supervised by experts, DIP not only saves time but also helps improve the chance that a clinical trial will succeed. Its technology has already been proven in real cases, including an AI-written protocol approved by Japan’s regulator with no revisions. Today, DIP works with over 1,000 life science companies worldwide, including major names like Bayer, Johnson & Johnson, and Roche.
Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 82
- Round size: Seed $1.4k–$28M; Series A $297k–$37M; Series B $7.3M–$58M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
- UniXell Biotechnology — Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 574
- Round size: Series A $1.5M–$35M; Series B $8M–$55M; Series C $25M–$105M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- uban — Uban provides an internet office leasing and trading services platform that helps to connect owners, customers and brokers, corporate customers in order to provide office rental and follow-up services, enabling its clients to receive real estate related services through a single portal. The company is based in Beijing, China.
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Darma — DARMA - Digital Healt
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 306
- Round size: Seed $1.5M–$100M; Series A $1.4M–$30M; Series B $3.2M–$100M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- CellWall — Cellwall is a desktop robot developer focused on the research, development, upgrade, and marketing of its initial product, CyboPal ONE.
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
- Chengdu Zhongweida Xinko Technology — Chengdu Zhongweida Xinko Technology is an IT firm that specializes in quantum computing and control technology products.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 357
- Round size: Seed $1.4k–$14M; Series A $1.6M–$44M; Series B $11M–$47M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Beta Infinite — Beta Infinite approaches data and model technologies in a distinctive and distinctive way.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 631
- Round size: Seed $443k–$15M; Angel $425k–$5.8M; Series A $1.4M–$30M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $140M in 2022
Portfolio highlights
- Ehang — Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field. With the combination of software and hardware techniques, it self-developed the communication and real-time viewing hardware and a smartphone operation system. Its product, Ghost, is accepted as the first truly smartphone app operated intelligentrobot, which is widely used in geographical information surveying, professional television aerial filming, roadshow displaying, disaster rescuing and delivery, surveillance and monitoring, and even expected to play important role in the future logistics areas.Ehang was founded in 2014 by makers from China, America, and Singapore who are enthusiastic about drone flying. The enterprise’s core members graduated from Tsinghua University, Peking University, and Duke University in America.
- Snowplus — SNOWPLUS is an e-cigarette brand that provides users with e-cigarette products through a combination of online and offline sales models. The products are available in 12 different types of flavors. The products use TrueFeel honeycomb ceramic atomization technology and Aeroflow intake. Technology; In addition to reference to the existing food-gradestandards in China, Xuejia has also passed a number of third-party certifications in terms of safety. The core components such as atomizing core and cigarette holder comply with the highest medical safety standards of the FDA and the European Union.
- Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shanlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive High-growth segments such as surgical instrumentsand medical robots, and medical services. It has invested in 15 medical star companies such as Guoke Hengtai, Ricky Surgery, Jingyi Medical, Haipulos, Langhe Medical, etc. The core team of Shanlan Capital is the founder of the medical industry listed company, professional financial and strategic investment. Composition of people, in strategy formulation, talent introduction, technology research and development, market camp..
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 35
- Round size: Seed $1.4M–$14M; Series A $1.4M–$16M; Series B $1.5M–$28M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Bochuang Biotechnology — Bochuang Biotechnology is a cutting-edge medical repair product developer that specializes in the controllable electrochemical assembly of biomacromolecules. Bochuang Biotechnology is creating a line of high-end biological tissue functional membranes and derived medical device solutions.
- Insight Technology — Insight Technology is an instrument manufacturer and seller company that specializes in instrument sales, intelligent instrument sales, mechanical equipment research and development, and more.
- Yangshan Medical Technology — Yangshan Medical Technology is a Shanghai-based company specializing in dental surgery robots.
Long Hill Capital is a next generation thesis-driven venture capital firm. We invest in technology-enabled healthcare and consumer services companies which seek to massively improve health and quality of life for every Chinese.Since 2005 the founding team of Long Hill Capital have led the China investing practice for New Enterprise Associates(NEA), a global investment firm with over $17 billion in committed capital. They are joined by an experienced team of investment and operations professionals from such firms as Matrix Partners China and Morningside VC. Together the Long Hill Capital team have over 30 years of China venture capital experience and over 15 years of senior operating experience at some of China’s most successful technology and healthcare companies including Alibaba, Huawei and Ping’an Good Doctor.Over the course of their venture capital careers, the Long Hill Capital team have invested in such industry leading companies as CITIC Pharmaceutical, WeDoctor, Hygeia Medical Services, GST Clinics, LineKong, LianLian Pay, Ele.Me, TheBeastShop and more.
Show more...Investment focus
- Industry: Medical, Health Care, Training
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 46
- Round size: Series A $1.9M–$20M; Series B $7.5M–$31M; Series C $15M–$60M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $300M in 2021
Portfolio highlights
- Filan Air — Filan Air develops technology for improving air quality, such as air treatment for medical laboratories.
- Oushisheng Technology — Oushisheng Technology is a national high-tech company that provides complete solutions for micro-reaction flow chemistry to people all over the world.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focus its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.Fortune Capital is ranked among thehighest performing VC/PE firms in China and selected as "Vice President of Venture Capital Committee of IAC," "Vice President of Shenzhen VC Association," "Vice President of Shenzhen Chamber of International Investment & Funding," etc.In addition to providing capitals, Fortune Capital provides its investee companies with personalized value-added services.
Show more...Investment focus
- Industry: Manufacturing, Software, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, Japan, United States
Investor stats
- Total investments: 297
- Round size: Seed $462k–$73M; Series A $1.5M–$70M; Series B $3M–$57M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $860M in 2021
Portfolio highlights
- Xinjie Energy — Xinjie Energy focuses on the research, development, and production of lithium metal solid-state batteries. These batteries aim to offer energy density and improved safety compared to traditional lithium-ion batteries. The company works on advancing battery technology, with potential applications in electric vehicles and energy storage. It isinvolved in advancing solid-state battery technology and expanding its presence in the battery industry.
- Strongest Laser — Strongest Laser is a high-power fiber laser equipment developer.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Sinovation Ventures is a full-service venture capital firm that actively invests in the Chinese technology market.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 330
- Round size: Seed $1.3M–$14M; Series A $1.5M–$32M; Series B $4M–$74M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $203M in 2022
Portfolio highlights
- Gestala — Gestala is China’s first pioneer in ultrasound-based Brain-Computer Interface (BCI). We are dedicated to engineering a platform with full-brain read-write capabilities, offering transformative therapeutic modalities for neurological disorders. Beyond clinical impact, we aim to decode the neural code and pave the way for a symbiotic future wherebrain science and artificial intelligence converge.
- Jiangxian Technology — Jiangxian Technology is a company focused on embodied intelligence, a field that integrates artificial intelligence with physical systems such as robots and smart devices, enabling machines to perceive, learn from, and interact with the real world in a more human-like and adaptive manner across applications like automation, healthcare, and advancedmanufacturing.
- Ruilian Intelligent Computing — Ruilian Zhisuan is an AI computing infrastructure innovator that provides integrated hardware software solutions. Modeled after Google's Jupiter optoelectronic architecture, it features full stack OCS scheduling to replace traditional electronic switches with optical routing. This core technology drastically minimizes network latency andsystem power consumption for advanced AI calculation networks.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 217
- Round size: Series A $1.5M–$55M; Series B $10M–$100M; Series C $14M–$200M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- ChipSine — ChipSine is an Integrated Circuit (IC) design company that focuses on the research and development of automotive-grade electronic control chips.
- Empower — Empower is an enterprise platform focused on intelligent laser manufacturing that makes lasers smart.
- Neowise — XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Software
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 228
- Round size: Angel $425k–$2.9M; Series A $1.4M–$94M; Series B $3M–$150M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2025
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- IO-AI Tech — IO-AI Tech develops specialized data infrastructure to connect physical robots, AI models, and real-world training environments. The company's core value proposition relies on its end-to-end hardware and software products—such as teleoperation tools and motion capture units—which allow developer teams to capture, visualize, and managehigh-precision multimodal data. By automating complex data pipelines and annotations, the business model scales the collection of high-quality training assets essential for deploying frontier physical intelligence.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.
Show more...Investment focus
- Industry: E-Commerce, Manufacturing, Software
- Stage:Series A, Angel, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 285
- Round size: Seed $1.4M–$14M; Angel $425k–$7M; Series A $1.4M–$38M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2025
Portfolio highlights
- Quantex — Quantex is committed to focusing on the next generation of information technology and integrated circuit fields, and is dedicated to the in-depth research and development of 3.2T/6.4T photonic integrated chips (PIC), optical modules and CPO (co-packaged optics) solutions, leading the localization of high-end optical transmission chips.
- XinYang Micro — Xinyangwei is an early stage underwater sensing chip startup specializing in CMUT (Capacitive Micromachined Ultrasonic Transducer) technology. The company provides integrated acoustic sensing modules and 3D imaging components designed to give pool cleaning robots intelligent near field path planning and mapping capabilities.
- ChipSense Technology — ChipSense Technology is a semiconductor focused on developing high-performance chips for AI computing infrastructure. The company provides chip solutions that enable perception and efficiency management in AI computing centers, helping optimize resource utilization, operational efficiency, and intelligent management of large-scale AI computingclusters.
Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech and high-tech enterprises with core competitiveness in the initial stage and growth stage..
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, India
Investor stats
- Total investments: 78
- Round size: Seed $42k–$72M; Series A $709k–$97M; Series B $2M–$40M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Zhitong Technology — Zhitong Medical is a provider of computational imaging technology that focuses on the development of surgical vision.
- Fulinlan Technology — Fulinlan is committed to the planning, design, development, structural analysis, equipment processing and installation of non-standard proprietary equipment, precision parts and other products in the field of aerospace.
- Torrey Pines Medicine — Torrey Pines Medicine is a biotechnology business focused on creating next-generation ultra-long-acting peptide therapies for metabolic illnesses.
Tiantu Capital is a venture capital association.
Show more...Investment focus
- Industry: Food and Beverage, E-Commerce, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, United States, Japan
Investor stats
- Total investments: 140
- Round size: Seed $7M–$20M; Series A $1.5M–$16M; Series B $10M–$146M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $75M in 2019
Portfolio highlights
- Zdeer — Zdeer is a health tech brand focusing on artificial intelligence health and consumer medicine. It is committed to improving the health awareness of the whole people, while breaking the shackles of the traditional health industry, through continuous technological innovation and product innovation, to bring better-looking and better-use products toconsumers at a more affordable price.
- DeyeeMed — DeyeeMed is a globally recognized professional artificial intelligence medical robot company that combines R&D, manufacture, sales, and service training.
- Billy Information — Mycooltv leverage advanced AI technology to create cost-effective solutions for premium hotel experiences. AI travel media network.
Beijing Huafang Investment focuses on the investment and management of state-owned capital and its investment covers commercial real estate.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 26
- Round size: Seed $13M–$14M; Series A $14M–$30M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- ClonOrgan — ClonOrgan has developed a technology to humanize pig cells that will grow into human-compatible organs.The business specializes in xenotransplantation and has a one-stop R&D platform that includes raising gene-edited pigs, preclinical testing, and breeding. It is dedicated to addressing the critical shortage of clinical organ transplantationand creating the organ factory of the future.ClonOrgas was established in 2005 in Chengdu, Sichuan.
- Kaiwang Data — Kaiwang Data is a one-stop shop for data solutions. It focuses on offering complete data labeling solutions for automakers and businesses involved in autonomous driving.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Medical VC funding in China at a glance
Stats across 3.6k deals from 3.5k investors.
Access all 3480 VC funds in China Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical VC Funds in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 3480 VC funds investing in China Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!